For patients with estrogen receptor-positive, HER2-negative advanced breast cancer, the moment a tumor progresses on a CDK4/6 inhibitor can feel like a therapeutic cliff. These drugs, including palbociclib, ribociclib and abemaciclib, have transformed first-line treatment by slowing the cell cycle and delaying chemotherapy for many patients. But resistance is common, and the best strategy after progression remains uncertain. Now, an international real-world study suggests that adding the targeted drug everolimus to endocrine therapy may hold the disease at bay for slightly longer than endocrine therapy alone—but the gain is small, and toxicity means the treatment is unlikely to suit everyone.

The study, called EVERGREEN, analyzed outcomes for 207 women whose estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer had progressed after treatment with a CDK4/6 inhibitor. Of these patients, 150 received everolimus alongside endocrine therapy, while 57 received endocrine therapy without everolimus. After a median follow-up of 31.8 months, the median real-world progression-free survival was 5.0 months in the everolimus group, compared with 4.3 months among those given endocrine therapy alone. The adjusted hazard ratio for progression or death was 0.68, with a 95 percent confidence interval of 0.47 to 0.99.

That result means the everolimus-containing treatment was associated with an approximately 32 percent lower relative risk of progression or death during the study period after statistical adjustment. It does not mean that every patient gained a fixed additional 32 percent of survival, nor that the cancer was controlled for 32 percent longer. The absolute difference in median progression-free survival was only 0.7 months—roughly three weeks. The researchers therefore describe the benefit as modest. There was no statistically significant improvement in the time until chemotherapy was needed or in overall survival, the measure that most directly captures whether treatment helps patients live longer.

Everolimus attacks a different part of the machinery that cancer cells use to grow. It inhibits mammalian target of rapamycin, or mTOR, a central signaling protein that helps regulate protein production, cell growth, metabolism and survival. In hormone receptor-positive breast cancer, signaling through the estrogen receptor can cooperate with the PI3K–AKT–mTOR pathway to keep malignant cells dividing even when estrogen-driven growth is being suppressed. Laboratory studies have suggested that increased activity in this pathway can contribute to resistance against CDK4/6 inhibition. By blocking mTOR while continuing endocrine therapy, clinicians aim to shut down a bypass route that cancer cells may exploit after cell-cycle treatment stops working.

The biological rationale, however, does not guarantee a large clinical effect. Tumors that acquire resistance to CDK4/6 inhibitors are not uniform. Some develop alterations in genes such as ESR1, which encodes the estrogen receptor; others involve the PI3K–AKT–mTOR network, including PIK3CA, AKT1 or PTEN. Still others may become less dependent on estrogen signaling altogether, switch to alternative growth programs or contain several resistant subclones at once. Everolimus may be most useful when the mTOR pathway remains an important engine of tumor growth, but the EVERGREEN study did not establish a biomarker that could reliably identify such patients before treatment.

The study’s design is important for interpreting its findings. EVERGREEN was a multicentre, international, retrospective quasi-experimental study rather than a randomized clinical trial. The investigators compared women treated at centers where everolimus plus endocrine therapy was the standard approach with women treated at centers where endocrine therapy alone was standard. This approach can provide valuable evidence from routine oncology practice, especially when randomized trials have not answered a specific treatment question. It also introduces potential sources of bias: treatment policies differ between hospitals, physicians may select everolimus for particular types of patients, and medical records may not capture every factor influencing treatment choice or disease assessment.

The patient groups were broadly balanced at baseline, according to the researchers, but the everolimus cohort had received a greater number of previous lines of therapy. That imbalance matters because heavily pretreated disease can be more biologically resistant and patients may have poorer overall health or fewer remaining treatment options. The investigators used adjusted analyses to account for measured differences, but statistical methods cannot completely remove the effects of unknown or unrecorded factors. “Real-world progression-free survival” is also less tightly controlled than progression-free survival in a prospective trial, where imaging schedules, response assessments and follow-up procedures are standardized.

The safety findings were consistent with earlier reports of everolimus, but the abstract does not provide a detailed breakdown of adverse events. The drug can cause mouth inflammation, rash, fatigue, diarrhea, metabolic changes and suppression of blood-cell production; it can also produce noninfectious pneumonitis, an inflammatory lung complication. These risks are particularly relevant in advanced cancer, where maintaining quality of life is a central treatment goal. A therapy that delays progression by several weeks may be worthwhile for a carefully selected patient who wants to remain on oral treatment and has limited alternatives, but less attractive for someone vulnerable to complications or eligible for a better-matched molecular therapy.

The findings arrive in a rapidly changing treatment landscape. After CDK4/6 inhibitor progression, options may include endocrine drugs designed to target specific resistance mutations, inhibitors of PI3K or AKT signaling, antibody–drug conjugates and chemotherapy. For example, the presence of an ESR1 mutation or an alteration in PIK3CA, AKT1 or PTEN may influence the suitability of other targeted approaches, although the best sequence of therapies is still evolving. The EVERGREEN results do not show that everolimus should replace these options. Instead, they suggest that it remains a possible strategy for a subset of patients whose disease is still endocrine-sensitive and for whom the expected benefits outweigh the drug’s side effects.

The study also illustrates why treatment after CDK4/6 resistance cannot be reduced to a single universal prescription. A median benefit measured in weeks can conceal meaningful differences between individuals: some patients may experience little response, while others may achieve substantially longer disease control. Future trials will need to connect outcomes to tumor biology, circulating tumor DNA, prior endocrine exposure and the pattern of progression. For now, EVERGREEN provides a cautiously encouraging but not practice-revolutionizing message: everolimus can add a small amount of control after CDK4/6 inhibitors, but the decision to use it should be individualized rather than automatic.

The estrogen receptor has long been recognized as a critical driver of breast cancer proliferation in ER+ tumors. Conventional therapies primarily rely on endocrine treatment strategies that either block the receptor’s activity or reduce estrogen production. However, resistance mechanisms frequently emerge, rendering these treatments less effective over time and leading to disease progression. The new therapeutic paradigm investigated in this phase 1 trial focuses not merely on inhibiting the receptor but on actively degrading it, thereby offering the potential to overcome resistance and achieve more sustained tumor suppression.

At the core of this study lies a class of compounds known as selective estrogen receptor degraders (SERDs). These molecules operate by binding to the estrogen receptor and promoting its degradation via the ubiquitin-proteasome system, effectively eliminating the receptor from cancer cells. This process halts the aberrant signaling cascade that fuels tumor growth. While previous generations of SERDs have shown clinical promise, issues such as suboptimal bioavailability and adverse side effects have limited their widespread use. The investigational drug assessed in this trial represents a significant refinement, demonstrating improved pharmacokinetics and tolerability.

The phase 1 trial enrolled patients with advanced or metastatic ER+/HER2– breast cancer who had exhausted standard treatment options. The primary objectives were to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the novel ER degrader. Patients received escalating doses of the compound, monitored closely for adverse effects, and underwent comprehensive biomarker analyses to elucidate the drug’s mechanism of action and impact on tumor biology.

Encouragingly, the investigational agent exhibited a favorable safety profile, with most adverse events being mild to moderate and manageable. Importantly, no dose-limiting toxicities emerged during the study, allowing for the identification of an optimal dosing regimen. Pharmacokinetic data revealed that the drug achieved therapeutic plasma concentrations rapidly and maintained them with once-daily oral administration, a noteworthy advantage over previous SERDs requiring more complex dosing strategies.

Preliminary efficacy signals were equally promising, with several patients exhibiting partial responses or stable disease lasting multiple months. These early tumor responses, observed even in heavily pretreated populations, underscore the potential of ER degradation as a viable strategy to circumvent resistance to classical endocrine therapies. Moreover, biomarker assessments confirmed robust downregulation of estrogen receptor expression and suppression of downstream signaling pathways, validating the intended mechanism of therapeutic action.

The implications of these findings resonate strongly within the oncology community. By advancing beyond receptor blockade to receptor elimination, this therapy could redefine the clinical management of ER+ breast cancer, particularly for patients with metastatic disease who face limited options. Although this phase 1 study primarily addresses safety and early efficacy, its results lay the groundwork for larger, randomized trials to establish definitive clinical benefit and elucidate long-term outcomes.

One of the notable scientific achievements of this trial is the integration of cutting-edge molecular diagnostic techniques. High-throughput sequencing, circulating tumor DNA analysis, and advanced imaging modalities were employed to monitor treatment response in real-time and identify molecular correlates of efficacy and resistance. These comprehensive datasets enrich our understanding of tumor heterogeneity and adaptive mechanisms, potentially guiding personalized treatment strategies in the future.

Furthermore, the study’s design exemplifies the growing trend toward precision oncology, wherein therapies are tailored based on individual tumor biology rather than a one-size-fits-all approach. The selective degradation of estrogen receptors targets a fundamental vulnerability specific to ER+ cancers, sparing non-tumor tissues and minimizing systemic toxicity, thereby enhancing the therapeutic window.

The successful implementation of selective ER degradation also stimulates a broader reevaluation of receptor-targeted therapies across cancer types. By harnessing the cell’s own protein degradation machinery, similar strategies could be adapted to target other oncogenic receptors that have historically been challenging to inhibit effectively. This trial thus serves as a proof-of-concept not only for breast cancer treatment but as a beacon for drug development in oncology at large.

While the current findings generate significant optimism, several questions remain to be addressed. The durability of clinical responses, optimal sequencing with other therapeutic modalities, and potential resistance pathways to ER degraders warrant comprehensive investigation. Additionally, identifying predictive biomarkers to select patients most likely to benefit will be crucial for maximizing clinical impact.

Collaboration among academic institutions, pharmaceutical industry partners, and regulatory agencies will be vital to accelerate the development and approval of this promising therapeutic class. The speed and rigor with which this early-phase trial was conducted exemplify the collaborative spirit essential to translating bench science into transformative clinical solutions.

In summary, the phase 1 trial led by Hamilton, Layman, Cosgrove, and colleagues represents a milestone in breast cancer research by demonstrating the feasibility, safety, and preliminary efficacy of ER degradation in advanced ER+/HER2– breast cancer. This novel approach could ultimately reshape treatment paradigms, offering hope to patients confronted with aggressive disease and limited therapeutic options. As the oncology field eagerly anticipates forthcoming phase 2 and 3 studies, the potential to improve survival and quality of life for millions of patients worldwide shines brighter than ever.

The journey from conceptual innovation to clinical application continues, propelled by relentless scientific inquiry and patient-centered research. Selective estrogen receptor degradation stands poised to become an integral weapon in the arsenal against breast cancer, transforming outcomes and exemplifying the power of targeted molecular therapy.

Subject of Research:
Advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2–) breast cancer treatment through selective estrogen receptor degradation.

Article Title:
ER degradation for ER⁺/HER2– advanced or metastatic breast cancer: a phase 1 trial.

Article References:
Hamilton, E., Layman, R.M., Cosgrove, D. et al. ER degradation for ER⁺/HER2– advanced or metastatic breast cancer: a phase 1 trial. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67485-y

Image Credits: AI Generated